Rationale and design of the FRENch CoHort of myocardial Infarction Evaluation (FRENCHIE) study - 14/06/24

Doi : 10.1016/j.acvd.2024.04.004

Alexandre Gautier ^a,^b, Nicolas Danchin ^c, Gregory Ducrocq ^a,^b, Alexandra Rousseau ^d, Yves Cottin ^e, Guillaume Cayla ^f, Fabrice Prunier ^g, Isabelle Durand-Zaleski ^h,ⁱ, Philippe Ravaud ^h, Denis Angoulvant ^j, Pierre Coste ^k, Gilles Lemesle ^l, Claire Bouleti ^m, Batric Popovic ⁿ, Emile Ferrari ^o, Johanne Silvain ^p, Olivier Dubreuil ^q, Thibault Lhermusier ^r, Pascal Goube ^s, François Schiele ^t, Gérald Vanzetto ^u, Victor Aboyans ^v, Romain Gallet ^w, Hélène Eltchaninoff ^x,^y,^z, Christophe Thuaire ^aa, Jean-Guillaume Dillinger ^a,^ab, Franck Paganelli ^ac, Julie Gourmelen ^ad, Philippe Gabriel Steg ^a,^b,^ae,^{^{1
Twitter handle: @gabrielsteg.},}^⁎ , Tabassome Simon ^d
on behalf of the FRENCHIE investigators
^a French Alliance for Cardiovascular Trials, Laboratory for Vascular Translational Science, Inserm U1148, hôpital Bichat, AP–HP, 75018 Paris, France
^b Université Paris Cité, 75006 Paris, France
^c Hôpital européen Georges-Pompidou, AP–HP, 75015 Paris, France
^d Department of Clinical Pharmacology and Clinical Research Platform of the East of Paris (URC-CRC-CRB), French Alliance for Cardiovascular Trials, Hôpital Saint-Antoine, AP–HP, Sorbonne University, 75012 Paris, France
^e CHU François-Mitterrand, université de Bourgogne, 21000 Dijon, France
^f CHU de Nîmes, université de Montpellier, 30900 Nîmes, France
^g Équipe Carme, CNRS, Mitovasc, Inserm, CHU d’Angers, université d’Angers, 49100 Angers, France
^h URC-Eco, service d’épidémiologie clinique, hôpital de l’Hôtel Dieu, AP–HP, CRESS, Inserm, INRAE, université Paris Cité, 75004 Paris, France
ⁱ Santé Publique hôpital Henri-Mondor, 94000 Créteil, France
^j Service de cardiologie, CHRU de Tours, UMR Inserm 1327 ISCHEMIA, université de Tours, 37000 Tours, France
^k Service des maladies coronaires et vasculaires, hôpital cardiologique, CHU de Bordeaux, université de Bordeaux, 33604 Pessac, France
^l USIC et centre hémodynamique, institut cœur poumon, Institut Pasteur de Lille, INSERM UMR1011, French Alliance for Cardiovascular Trials, CHU de Lille, faculté de médecine de l’université de Lille, 59019 Lille, France
^m Cardiology Department, Clinical Investigation Centre (Inserm 1204), CHU de Poitiers, 86000 Poitiers, France
ⁿ Département de cardiologie, CHRU de Nancy, université de Lorraine, 54500 Vandoeuvre-lès-Nancy, France
^o Service de cardiologie, hôpital Pasteur, CHU de Nice, 06000 Nice, France
^p ACTION Group, Inserm UMRS 1166, Sorbonne université, hôpital Pitié-Salpêtrière, AP–HP, 75013 Paris, France
^q USIC, service de cardiologie, hôpital Saint-Joseph Saint-Luc, 69007 Lyon, France
^r Service de cardiologie, UFR Santé de Toulouse, université Toulouse III Paul-Sabatier, CHU de Toulouse, 31400 Toulouse, France
^s Service de cardiologie, CH Sud-Francilien, 91100 Corbeil-Essonnes, France
^t Department of Cardiology, University Hospital Jean Minjoz, EA3920, University of Burgundy Franche-Comte, 25000 Besançon, France
^u Université Grenoble Alpes, Inserm U1039, CHU de Grenoble Alpes, 38700 La Tronche, France
^v Department of Cardiology, Dupuytren-2 University Hospital, EpiMaCT, Inserm 1098/IRD270, Limoges University, 87042 Limoges, France
^w Service de cardiologie, hôpital Henri-Mondor, AP–HP, 94000 Créteil, France
^x Inserm U955-IMRB, UPEC, 94010 Créteil, France
^y École nationale vétérinaire d’Alfort, 94700 Maisons-Alfort, France
^z Département de cardiologie, CHU de Rouen, Inserm U1096, université de Rouen Normandie, 76000 Rouen, France
^aa Centre hospitalier Louis-Pasteur, 28018 Chartres, France
^ab Department of Cardiology, hôpital Lariboisière, AP–HP, Inserm U-942, 75010 Paris, France
^ac Centre for CardioVascular and Nutrition Research (C2VN), INSERM, INRAE and Aix-Marseille University, 13005 Marseille, France
^ad Inserm, UMS 011, Population-Based Epidemiological Cohorts, 94807 Villejuif, France
^ae Institut universitaire de France, 75231 Paris, France

^⁎Corresponding author. Department of Cardiology, Hôpital Bichat, AP–HP, 46, rue Henri-Huchard, 75018 Paris, France.Department of Cardiology, Hôpital Bichat, AP–HP46, rue Henri-HuchardParis75018France

Graphical abstract

Nested studies in the FRENCHIE (FRENch CoHort of myocardial Infarction Evaluation) registry. Randomized clinical trials (RCTs) are in red; observational registries are in blue. Lp(a): lipoprotein(a); MI: myocardial infarction; SNDS: Système National des Données de Santé (French national health database).

Nested studies in the FRENCHIE (FRENch CoHort of myocardial Infarction Evaluation) registry. Randomized clinical trials (RCTs) are in red; observational registries are in blue. Lp(a): lipoprotein(a); MI: myocardial infarction; SNDS: Système National des Données de Santé (French national health database).

Le texte complet de cet article est disponible en PDF.

Highlights

•	Contemporary epidemiology and outcomes of AMI in France.
•	Identification of emerging risk factors and new prognostic determinants of AMI.
•	Long-term follow-up by automated link with the French national health database.
•	Healthcare consumption and medico-economic impact of myocardial infarction.
•	Platform for cohort-nested studies, both observational and randomized.

Le texte complet de cet article est disponible en PDF.

Abstract

Background

Despite major advances in prevention and treatment, cardiovascular diseases – particularly acute myocardial infarction – remain a leading cause of death worldwide and in France. Collecting contemporary data about the characteristics, management and outcomes of patients with acute myocardial infarction in France is important.

Aims

The main objectives are to describe baseline characteristics, contemporary management, in-hospital and long-term outcomes of patients with acute myocardial infarction hospitalized in tertiary care centres in France; secondary objectives are to investigate determinants of prognosis (including periodontal disease and sleep-disordered breathing), to identify gaps between evidence-based recommendations and management and to assess medical care costs for the index hospitalization and during the follow-up period.

Methods

FRENCHIE (FRENch CoHort of myocardial Infarction Evaluation) is an ongoing prospective multicentre observational study (ClinicalTrials.gov Identifier: NCT04050956) enrolling more than 19,000 patients hospitalized for acute myocardial infarction with onset of symptoms within 48hours in 35 participating centres in France since March 2019. Main exclusion criteria are age<18 years, lack of health coverage and procedure-related myocardial infarction (types 4a and 5). Detailed information was collected prospectively, starting at admission, including demographic data, risk factors, medical history and treatments, initial management, with prehospital care pathways and medication doses, and outcomes until hospital discharge. The follow-up period (up to 20 years for each patient) is ensured by linking with the French national health database (Système national des données de santé), and includes information on death, hospital admissions, major clinical events, healthcare consumption (including drug reimbursement) and total healthcare costs. FRENCHIE is also used as a platform for cohort-nested studies – currently three randomized trials and two observational studies.

Conclusions

This nationwide large contemporary cohort with very long-term follow-up will improve knowledge about acute myocardial infarction management and outcomes in France, and provide a useful platform for nested studies and trials.

Le texte complet de cet article est disponible en PDF.

Keywords : Acute myocardial infarction, Acute coronary syndrome, Epidemiology, Cardiovascular risk factor, Registry-nested clinical study

Plan

Objectives and outcomes

Data collection and evaluation

Mid- and long-term follow-up

Disclosure of interest

Funding

☆	Tweet: FRENCHIE is a multicentre cohort of French MI patients, combining extensive data collection in the acute phase, long-term comprehensive follow-up via SNDS linkage and allowing to perform cohort-nested studies. One important aim is to identify areas requiring improved management.

Export

Vol 117 - N° 6-7

P. 417-426 - juin 2024 Retour au numéro

Article précédent

Sacubitril/valsartan has an underestimated impact on the right ventricle in patients with sleep-disordered breathing, especially central sleep apnoea syndrome
Laura Sofia Cardelli, Mariarosaria Magaldi, Audrey Agullo, Gaetan Richard, Erika Nogue, Philippe Berdague, Michel Galiner, Frédéric Georger, François Picard, Elvira Prunet, Nicolas Molinari, Arnaud Bourdin, Dany Jaffuel, François Roubille

| Article suivant

Target population for a selective cardiac myosin inhibitor in hypertrophic obstructive cardiomyopathy: Real-life estimation from the French register of hypertrophic cardiomyopathy (REMY)
Alessandro Parodi, Tania Puscas, Patricia Réant, Erwan Donal, Dorra M’Barek Raboudi, Clarisse Billon, Anne Bacher, Mohamed El Hachmi, Karim Wahbi, Xavier Jeunemaître, Albert Hagège, REMY Working Group of the French Society of Cardiology

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Rationale and design of the FRENch CoHort of myocardial Infarction Evaluation (FRENCHIE) study - 14/06/24

Graphical abstract

Highlights

Abstract

Background

Aims

Methods

Conclusions

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL